TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35978306

Group type: EXPERIMENTAL
Intervention: ValueCare intervention (ICT-enabled value-based methodology for integrated care)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 240
Study: 34063083

Group type: EXPERIMENTAL
Intervention: Intermittent fasting and glucose administration paired with relaxation and guided imagery
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 32
Study: 32368355

Group type: EXPERIMENTAL
Intervention: IVC and mEHT plus best supportive care (BSC)
Number of subjects: 97

Group type: COMPARATOR
Intervention: BSC alone
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: IVC and mEHT plus BSC
Number of subjects: 97
Study: 34855460

Group type: EXPERIMENTAL
Intervention: CD34-selected peripheral blood stem cell
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: PTCy after bone marrow graft
Number of subjects: 346

Group type: COMPARATOR
Intervention: Tacrolimus and methotrexate after bone marrow graft (control)
Number of subjects: 346
Study: 32789011

Group type: EXPERIMENTAL
Intervention: Optimised information materials
Number of subjects: 11531

Group type: COMPARATOR
Intervention: Standard trial information
Number of subjects: 11531
Study: 36054786

Group type: EXPERIMENTAL
Intervention: Jaktinib 100 mg BID
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Jaktinib 200 mg QD
Number of subjects: 118
Study: 33217336

Group type: EXPERIMENTAL
Intervention: Intervention not specified
Number of subjects: 0
Study: 33614436

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided serratus plane block (UGSPB)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Intravenous methadone
Number of subjects: 4
Study: 35880768

Group type: EXPERIMENTAL
Intervention: Fee-for-service payment
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Pay-for-performance incentives
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Grant funds
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Collaborative Care Management billing (CPT) codes
Number of subjects: 44

Group type: COMPARATOR
Intervention: Fee-for-service and pay-for-performance incentives
Number of subjects: 44

Group type: COMPARATOR
Intervention: Grants and/or general medical education funds
Number of subjects: 44
Study: 34171356

Group type: EXPERIMENTAL
Intervention: WaveOne Gold (WOG) system
Number of subjects: 148

Group type: COMPARATOR
Intervention: XP-endo Shaper (XPES) system
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Both WOG and XPES systems
Number of subjects: 148
Study: 32001844

Group type: EXPERIMENTAL
Intervention: Newborn service readiness assessment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: General requirements, equipment, medicines and commodities, staffing and guidelines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Training of staff
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transportation and heater for room temperature maintenance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Training coverage
Number of subjects: 0
Study: 35182045

Group type: EXPERIMENTAL
Intervention: Roxadustat 200 mg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Roxadustat 200 mg with simvastatin dosed 2 hours before, and 4 and 10 hours after
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Roxadustat 200 mg with a statin
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Roxadustat 200 mg with statins
Number of subjects: 80
Study: 32398131

Group type: EXPERIMENTAL
Intervention: Integrated microfinance-group medical visit model for NCD, involving monthly group medical visits led by a community health educator and a rural clinician, tested over a 6-month pilot.
Number of subjects: 0
Study: 34273181

Group type: EXPERIMENTAL
Intervention: Use of Patient and Public Involvement (PPI) in RCTs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Consultation groups in RCTs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stages of trial process for PPI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methods of collecting opinions
Number of subjects: 0
Study: 32530172

Group type: EXPERIMENTAL
Intervention: Experimental group (eye tracking)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (direct collection of eye movement parameters)
Number of subjects: 40
Study: 33973398

Group type: EXPERIMENTAL
Intervention: Chiropractic care
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Exercise therapy
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Chiropractic care and Exercise therapy (combined)
Number of subjects: 50
Study: 32875536

Group type: EXPERIMENTAL
Intervention: Wearable-based physical activity intervention (Garmin Vivofit2® with behavioral feedback, goal setting, and health coaching)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Wearable-based physical activity intervention
Number of subjects: 83

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 83
Study: 34889150

Group type: EXPERIMENTAL
Intervention: Cervical plexus block (CPB)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Cervical plexus block (CPB) with translaryngeal block (Group ST)
Number of subjects: 29
Study: 35260464

Group type: EXPERIMENTAL
Intervention: Aspirin (81 mg two times a day)
Number of subjects: 20000

Group type: EXPERIMENTAL
Intervention: Low-intensity warfarin (INR target 1.7-2.2)
Number of subjects: 20000

Group type: EXPERIMENTAL
Intervention: Rivaroxaban (10 mg/day)
Number of subjects: 20000
Study: 34750128

Group type: EXPERIMENTAL
Intervention: Peer coaching program
Number of subjects: 290
Study: 32774189

Group type: EXPERIMENTAL
Intervention: Manual compression for hemostasis
Number of subjects: 46
Study: 34823375

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure treatment (exact dosage and duration not specified)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: HFpEF (EF ≥45%)
Number of subjects: 133
Study: 35189811

Group type: EXPERIMENTAL
Intervention: Eptinezumab 100 mg
Number of subjects: 1072

Group type: EXPERIMENTAL
Intervention: Eptinezumab 300 mg
Number of subjects: 1072

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1072

Group type: EXPERIMENTAL
Intervention: Eptinezumab (both doses)
Number of subjects: 1072
Study: 34038904

Group type: EXPERIMENTAL
Intervention: Snail Soothing and Repairing (SSR) cream applied twice daily for 14 days
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo applied twice daily for 14 days
Number of subjects: 22
Study: 36484185

Group type: EXPERIMENTAL
Intervention: Navel acupuncture, 30 min each time, once every other day, for 4 weeks
Number of subjects: 106

Group type: COMPARATOR
Intervention: Conventional treatment (drugs, catheterization, bladder function rehabilitation training)
Number of subjects: 106
Study: 34263648

Group type: EXPERIMENTAL
Intervention: Saffron total glycoside tablets (four tablets each time, three times each day for 6 months)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo (four tablets each time, three times each day for 6 months)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Saffron total glycoside tablets
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 32648464

Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 30

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 30
Study: 36220075

Group type: EXPERIMENTAL
Intervention: Natural Cycle
Number of subjects: 145

Group type: COMPARATOR
Intervention: Modified Natural Cycle
Number of subjects: 145
Study: 33010240

Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide 25 mg and emtricitabine 200 mg, and dolutegravir 50 mg
Number of subjects: 1053

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate 300 mg and emtricitabine 200 mg, and dolutegravir 50 mg
Number of subjects: 1053

Group type: COMPARATOR
Intervention: Tenofovir disoproxil fumarate 300 mg, emtricitabine 200 mg, and efavirenz 600 mg
Number of subjects: 1053

Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide, emtricitabine, and dolutegravir
Number of subjects: 1053

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate, emtricitabine, and dolutegravir
Number of subjects: 1053

Group type: COMPARATOR
Intervention: Tenofovir disoproxil fumarate, emtricitabine, and efavirenz
Number of subjects: 1053
Study: 34213361

Group type: EXPERIMENTAL
Intervention: Statements attributed to a female scientist
Number of subjects: 0

Group type: COMPARATOR
Intervention: Statements attributed to a male scientist
Number of subjects: 0
Study: 36209235

Group type: EXPERIMENTAL
Intervention: WGS-guided automated treatment recommendation strategy for individualized treatment of RR-TB
Number of subjects: 0

Group type: COMPARATOR
Intervention: RR-TB treatment according to the national South African guidelines
Number of subjects: 0
Study: 34076381

Group type: EXPERIMENTAL
Intervention: PRGF (plasma rich in growth factors)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: PRF (platelet-rich fibrin)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control (hemostatic sponge containing gentamicin)
Number of subjects: 43
Study: 34958359

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 or 10 mg twice daily
Number of subjects: 487

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 487
Study: 35966744

Group type: EXPERIMENTAL
Intervention: Moxibustion for harmonization of Yin and Yang
Number of subjects: 216

Group type: COMPARATOR
Intervention: Gentle moxibustion
Number of subjects: 216
Study: 32880493

Group type: EXPERIMENTAL
Intervention: Pulsed Radiofrequency (PRF) in addition to Transforaminal Epidural Steroid Injection (TFESI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Transforaminal Epidural Steroid Injection (TFESI) alone
Number of subjects: 0
Study: 616768357

Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 0

Group type: COMPARATOR
Intervention: No BCG vaccination (control)
Number of subjects: 0
Study: 36048481

Group type: EXPERIMENTAL
Intervention: HIIT intervention (INT)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Regular PE (CON)
Number of subjects: 45
Study: 33481506

Group type: EXPERIMENTAL
Intervention: PET-rainbow
Number of subjects: 50

Group type: COMPARATOR
Intervention: hot-metal new
Number of subjects: 50
Study: 35147583

Group type: EXPERIMENTAL
Intervention: Participants with viral load >400 copies/mL
Number of subjects: 7720

Group type: EXPERIMENTAL
Intervention: Male participants
Number of subjects: 7720

Group type: EXPERIMENTAL
Intervention: Asian participants
Number of subjects: 7720

Group type: EXPERIMENTAL
Intervention: Overall participants
Number of subjects: 7720
Study: 34145009

Group type: EXPERIMENTAL
Intervention: Individualised rehabilitation programme with five additional therapy sessions (one during hospitalisation, four in the municipality, and a follow-up phone call)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Individualised intervention component
Number of subjects: 14
Study: 32627192

Group type: COMPARATOR
Intervention: Self‐Compassion for Healthcare Communities (SCHC) program
Number of subjects: 58
Study: 33097204

Group type: EXPERIMENTAL
Intervention: Internal fixation with anterolateral plating, medial plating, or both
Number of subjects: 42

Group type: COMPARATOR
Intervention: Dual column plating
Number of subjects: 42
Study: 32410827

Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of autologous bone marrow-derived lineage-negative stem/progenitor cells (LIN- SPCs)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Standard therapy (control group)
Number of subjects: 34
Study: 34385269

Group type: EXPERIMENTAL
Intervention: Prognostic assessment and management pathway
Number of subjects: 498

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 498
Study: 34496357

Group type: EXPERIMENTAL
Intervention: Bursted percutaneous auricular vagus nerve stimulation (pVNS)
Number of subjects: 9
Study: 35353061

Group type: EXPERIMENTAL
Intervention: Reciproc (RC) files with reciprocating motion
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Twisted File Adaptive (TFA) system with adaptive motion
Number of subjects: 58
Study: 33795174

Group type: EXPERIMENTAL
Intervention: Tourniquet
Number of subjects: 327

Group type: COMPARATOR
Intervention: No Tourniquet
Number of subjects: 327
Study: 32536335

Group type: EXPERIMENTAL
Intervention: Quiet Mind Training (QMT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 30
Study: 32068197

Group type: EXPERIMENTAL
Intervention: Nurse-led program of care
Number of subjects: 152

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 152
Study: 35632653

Group type: EXPERIMENTAL
Intervention: GamCOVIDVac vaccine
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: EpiVacCorona vaccine
Number of subjects: 1000

Group type: COMPARATOR
Intervention: No specific vaccine (prior to vaccination)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Monitoring stages 1-3
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Monitoring stages 4-5
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Overall seropositivity
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Low anti-RBD Abs levels
Number of subjects: 1000

Group type: COMPARATOR
Intervention: High Ab levels
Number of subjects: 1000
Study: 33094519

Group type: EXPERIMENTAL
Intervention: Cotton swab sampling
Number of subjects: 205

Group type: COMPARATOR
Intervention: Stained smears (microscopic examination)
Number of subjects: 205
Study: 33422560

Group type: EXPERIMENTAL
Intervention: Proclarix risk score
Number of subjects: 457

Group type: COMPARATOR
Intervention: %free PSA (%fPSA)
Number of subjects: 457

Group type: COMPARATOR
Intervention: European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculator (RC)
Number of subjects: 457

Group type: EXPERIMENTAL
Intervention: Proclarix density
Number of subjects: 457

Group type: COMPARATOR
Intervention: PSA density
Number of subjects: 457
Study: 34445995

Group type: EXPERIMENTAL
Intervention: SMART model group (n=360)
Number of subjects: 840

Group type: COMPARATOR
Intervention: Usual care clinic group (n=360)
Number of subjects: 840

Group type: COMPARATOR
Intervention: Anticoagulation clinic group (n=120)
Number of subjects: 840
Study: 36078768

Group type: EXPERIMENTAL
Intervention: Home-based pulmonary rehabilitation programme (HPRP) for 8 weeks with two hospital sessions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Home-based pulmonary rehabilitation programme (HPRP)
Number of subjects: 0
Study: 33068293

Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (HFNC) oxygen therapy
Number of subjects: 22

Group type: COMPARATOR
Intervention: Conventional oxygen therapy (COT)
Number of subjects: 22
Study: 32395842

Group type: EXPERIMENTAL
Intervention: Hydrophobic dressing (Cutimed Sorbact®)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Silver dressing (Aquacel® Ag Extra)
Number of subjects: 204
Study: 36394933

Group type: EXPERIMENTAL
Intervention: Kombucha drink (KG), 220 ml, enriched with inulin (1.15 g/100 ml) for 10 days
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Kombucha drink (KG)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Water (Control Group, CG), 220 ml for 10 days
Number of subjects: 40
Study: 34587911

Group type: EXPERIMENTAL
Intervention: Beta-lactam antibiotics plus fluoroquinolones
Number of subjects: 139

Group type: COMPARATOR
Intervention: Beta-lactam antibiotics alone
Number of subjects: 139
Study: 34571050

Group type: EXPERIMENTAL
Intervention: Rifaximin‐α (550 mg BID)
Number of subjects: 38
Study: 32387064

Group type: EXPERIMENTAL
Intervention: Machine learning models (specifically the nonlinear XGBoost model)
Number of subjects: 26971

Group type: EXPERIMENTAL
Intervention: Machine learning models (linear logistic regression)
Number of subjects: 26971

Group type: EXPERIMENTAL
Intervention: Predicted intervention based on closing care gaps
Number of subjects: 26971

Group type: EXPERIMENTAL
Intervention: Prioritizing patients for intervention using predicted reduction in 1-year mortality risk
Number of subjects: 26971
Study: 32669450

Group type: EXPERIMENTAL
Intervention: Ixekizumab (80 mg every 2 weeks or every 4 weeks)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2

Group type: COMPARATOR
Intervention: Adalimumab (bDMARD-naïve only)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Ixekizumab (after rerandomization from placebo or adalimumab)
Number of subjects: 2
Study: 32703583

Group type: EXPERIMENTAL
Intervention: Initial intravenous bolus of low-dose heparin (40 IU/kg)
Number of subjects: 904
Study: 35337843

Group type: EXPERIMENTAL
Intervention: Hybrid Training System (HTS)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Sensory Transcutaneous Electrical Nerve Stimulation (TENS)
Number of subjects: 28
Study: 33740589

Group type: EXPERIMENTAL
Intervention: Caffeine 200 mg administered in a double-blind fashion during PAS or tACS
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: tACS (true) with caffeine
Number of subjects: 60

Group type: COMPARATOR
Intervention: tACS (sham) with caffeine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PAS and tACS
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Moderate caffeine consumption
Number of subjects: 60
Study: 32203971

Group type: EXPERIMENTAL
Intervention: 3MDR
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (non-specific treatment component)
Number of subjects: 43
Study: 35715198

Group type: EXPERIMENTAL
Intervention: NBO+EVT (100% oxygen via face mask, 10L/min for 4h)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: NBO+EVT
Number of subjects: 86
Study: 33262033

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Ketofol
Number of subjects: 75
Study: 34215667

Group type: EXPERIMENTAL
Intervention: Conventional genicular nerve radiofrequency ablation (GN‐RFA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 60
Study: 33289476

Group type: EXPERIMENTAL
Intervention: Biofeedback pelvic floor muscle training
Number of subjects: 300

Group type: COMPARATOR
Intervention: Basic pelvic floor muscle training
Number of subjects: 300
Study: 35902195

Group type: EXPERIMENTAL
Intervention: TEAS group (transcutaneous electrical acupoint stimulation)
Number of subjects: 1600
Study: 33463568

Group type: EXPERIMENTAL
Intervention: Alcaftadine 0.25%
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Olopatadine hydrochloride 0.2%
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Bepotastine besilate 1.5%
Number of subjects: 180

Group type: COMPARATOR
Intervention: Bepotastine and Alcaftadine
Number of subjects: 180
Study: 35301206

Group type: EXPERIMENTAL
Intervention: Endoscopic laser resection
Number of subjects: 100

Group type: COMPARATOR
Intervention: Endoscopic dilation
Number of subjects: 100
Study: 33129442

Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Number of subjects: 732
Study: 34498782

Group type: EXPERIMENTAL
Intervention: Targeted bronchiolitis interventions
Number of subjects: 1958
Study: 34753900

Group type: EXPERIMENTAL
Intervention: Egg Breakfast (EB)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Saturated Fat Breakfast (SB)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Eggs and Saturated Fat Breakfast (ES)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control Breakfast (CB)
Number of subjects: 48
Study: 36039846

Group type: EXPERIMENTAL
Intervention: Intensive intervention group (nutritional education at every outpatient visit)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Intensive intervention group
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (nutritional education once a year)
Number of subjects: 96
Study: 33320777

Group type: EXPERIMENTAL
Intervention: High-fructose corn syrup
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Aspartame
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Raw sugar
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Attempted to consume less sugar
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Attempted to consume less 'artificial' low-calorie sweeteners
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Attempted to consume less 'natural' low-calorie sweeteners
Number of subjects: 1000
Study: 33913260

Group type: EXPERIMENTAL
Intervention: Intravenous anifrolumab (150/300 mg once every 4 weeks)
Number of subjects: 819
Study: 35761841

Group type: EXPERIMENTAL
Intervention: PDL1/PD-1 inhibitors
Number of subjects: 116

Group type: COMPARATOR
Intervention: FOLFIRINOX regimen
Number of subjects: 116
Study: 33478890

Group type: EXPERIMENTAL
Intervention: Patient functional status (measured by Eastern Cooperative Oncology Group)
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: Quality of life (measured by Functional Assessment of Chronic Illness Therapy – Palliative Care)
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: Anxiety (measured by Hospital Anxiety and Depression Scale)
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: Depression (measured by Hospital Anxiety and Depression Scale)
Number of subjects: 441
Study: 34016828

Group type: EXPERIMENTAL
Intervention: Excessive screen time (more than 1 hour per day)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Screen time on weekdays
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Higher screen time correlation with mother's education
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Higher screen time correlation with family income
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Daycare attendance
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Caregivers' screen time
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Absence of digital-media rules
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Lower mother's education
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Watching educational digital content
Number of subjects: 400
Study: 35439521

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid and hypertonic dextrose
Number of subjects: 104

Group type: COMPARATOR
Intervention: Hyaluronic acid and normal saline
Number of subjects: 104
Study: 33857680

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Relapse Prevention (MBRP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 12-Step Facilitation (TSF)
Number of subjects: 0